Immune Checkpoint Inhibitors

The use of immune checkpoint inhibitors, which work by targeting molecules that serve as checks and balances in the regulation of immune responses, is a promising avenue of immunotherapeutic research in ovarian cancer.8 These strategies have shown efficacy in melanoma and are now being tested in lung cancer.9 Two drugs are already FDA-approved for metastatic melanoma, and three additional agents are anticipated to be approved by the end of 2015.6, 10


Continue Reading